CA-based Hillhurst Biopharmaceuticals secures an undisclosed amount in seed funding. Friedman Bioventure Fund led the round, and both new and old investors took part.
Utilising the funds, the business plans to speed up its Phase 2a clinical trials for sickle cell anaemia and another therapeutic indication.
Read also – CA-based ImpriMed Secures $23M in Series A Round Funding
Headquartered in the clinical stage and led by CEO Andrew Gomperts, Hillhurst Bio focuses on its exclusive GLASSTM platform, which opens the door for new drug products based on therapeutic gases that were previously restricted to inhaled delivery. These products involve a pipeline of innovative liquid therapeutic candidates indicated to treat patients suffering from acute pain, Parkinson’s disease, and sickle cell disease.
Read also – MO-based NewLeaf Symbiotics Secures $45M in Series D Round Funding
With an administration route intended to allow persistent usage in a home environment for patients with sickle cell disease, its main product, HBI-002, is an oral medicinal product candidate of low dose CO. Parkinson’s disease and other disorders associated with inflammation and cell death are examples of other possible disease targets.
About Hillhurst
Hillhurst is a clinical stage company focused on its proprietary GLASSTM platform, which enables novel drug products based on therapeutic gases that, up until now, have been limited by inhaled delivery, including a unique pipeline of novel liquid therapeutic candidates intended to treat patients with acute pain, sickle cell disease, and Parkinson’s disease.
Read also – TuMeke Raises $10M in Series A Funding led by Intel Capital
